Nintedanib Sandoz

Nintedanib, the active ingredient in Nintedanib Sandoz, is a tyrosine kinase inhibitor presented as a 100 mg oral capsule for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and is used in combination therapy for non‑small cell lung cancer.

GNH USA supplies Nintedanib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, with a focus on quality assurance, regulatory compliance, and reliable global logistics. The company ensures that each batch meets European Union standards for safety and efficacy.

Nintedanib is indicated for fibrotic lung diseases and as part of combination therapy for certain lung cancers. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening. - Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition when used with other agents.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools, often manageable with diet. - Abdominal pain: discomfort in the stomach area. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Elevated liver enzymes: indicates possible hepatic injury. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Cardiovascular events: rare cases of heart failure or hypertension exacerbation.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for potential complications. - Monitor liver function: obtain baseline and periodic ALT/AST tests. - Assess bleeding risk: avoid concomitant use with strong anticoagulants unless necessary. - Evaluate cardiovascular status: caution in patients with pre‑existing heart disease. - Avoid use in severe hepatic impairment: contraindicated when liver function is markedly compromised. - Store at ambient temperature: keep in the original pack, protect from moisture.

Nintedanib can interact with other medicines that affect its metabolism or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nintedanib exposure. - Concurrent anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding potential. - Other antifibrotic agents: additive toxicity risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly increase levels. - P‑glycoprotein inhibitors (e.g., verapamil): can affect drug transport. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.